dr. mcbride on biosimilar rituximab
Published 4 years ago • 115 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:30
dr. mcbride on the potential impact of bevacizumab biosimilars in oncology
-
1:17
dr. mcbride on the emergence of biosimilars in oncology
-
1:11
dr. mcbride on the regulatory pathway for biosimilars in oncology
-
1:35
dr. mcbride on the potential of biosimilars in oncology
-
5:59
dr ali mcbride discusses the role of biosimilars in oncology
-
1:23
dr. rule on rituximab biosimilar use in the uk
-
1:03
dr. eradat on rituximab biosimilar in cd20 b-cell nhl and cll
-
2:11
dr. lyman on rituximab biosimilars in non-hodgkin lymphoma
-
1:31
dr. welslau on the acceptance of rituximab biosimilar in dlbcl
-
2:15
dr. danilov on utility of rituximab biosimilars in cll
-
1:21
ali mcbride, pharmd, ms, bcps: pharmacists' concerns about biosimilar implementation
-
33:12
biosimilar therapy 101
-
0:41
similarity of biosimilars and biologics
-
1:40
dr. mato on rituximab biosimilars in cll
-
6:18
fda approves of biosimilar to infliximab – ibd in the news
-
7:22
an overview of biosimilarity
-
38:15
biosimilars and biologics
-
2:21
switching from a biologic to a biosimilar drug in canada
-
1:14
robert rifkin, md, on the impact of extrapolation and interchangeability on biosimilar use